Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT07928037
Overview
This study aims to assess real-world clinical outcomes among adult metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with and progressed on an androgen receptor pathway inhibitor (ARPI) who received 177Lu-PSMA-617 as a monotherapy or with concurrent ARPI. The study will use secondary data taken from a United States oncology database.
Sponsor
NovartisClinicalTrials.gov
NCT07928037Study contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Novartis Pharmaceuticals Study director
Drug / Compound
Eligibility
Help us improve your experience